TerminatedPHASE2, PHASE3NCT04378075

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

Studying Leigh syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
PTC Therapeutics
Principal Investigator
Vinay Penematsa, MD
PTC Therapeutics
Intervention
Vatiquinone(drug)
Enrollment
68 enrolled
Eligibility
20 years · All sexes
Timeline
20202023

Study locations (27)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04378075 on ClinicalTrials.gov

Other trials for Leigh syndrome

Additional recruiting or active studies for the same condition.

See all trials for Leigh syndrome

← Back to all trials